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ABSTRACT
The clinical utility ofmicroarray technologieswhenused in the context of prenatal diagnosis lies in the technology’s ability to
detect submicroscopic copy number changes that are associated with clinically signiﬁcant outcomes. We have carried out a
systematic review of the literature to calculate the utility of prenatal microarrays in the presence of a normal conventional
karyotype. Amongst 12362 cases in studies that recruited cases from all prenatal ascertainment groups, 295/12362 (2.4%)
overall were reported to have copy number changes with associated clinical signiﬁcance (pCNC), 201/3090 (6.5%) when
ascertained with an abnormal ultrasound, 50/5108 (1.0%) when ascertained because of increased maternal age and
44/4164 (1.1%) for all other ascertainment groups (e.g. parental anxiety andabnormal serumscreening result).Whenadditional
prenatalmicroarray studies are included in which ascertainment was restricted to fetuses with abnormal ultrasound scans,
262/3730 (7.0%)were reported to havepCNCs.© 2013 The Authors.Prenatal Diagnosispublished by JohnWiley& Sons Ltd.
Supporting information may be found in the online version of this article.
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INTRODUCTION
Over the past few years, microarray analysis, also known as
molecular karyotyping or chromosomal microarray analysis,
has gradually replaced conventional G-banded karyotyping as
the frontline diagnostic test for children and adults presenting
with a wide range of neurodevelopmental phenotypes with or
without associated congenital abnormalities.1–4 In many
countries, notably in the USA and Europe, the transfer from
karyotyping to microarrays in the postnatal constitutional
setting is now widespread, but the application of this
technology to prenatal cytogenetics has lagged behind the
postnatal implementation largely because of the perceived
difﬁculties of interpreting variants of unknown signiﬁcance
(VOUS) in the context of an ongoing antenatal diagnosis.
Prenatal microarrays have been more readily adopted in
speciﬁc situations. For example, the use of microarrays in cases
of known chromosomal abnormalities that were initially
identiﬁed by karyotyping allows for further characterisation
of the chromosomal breakpoints and the genes involved. Also,
a number of smaller prenatal studies have restricted the
comparison of microarrays and conventional karyotyping to
fetuses ascertained with ultrasound abnormalities.5–13
Recently, several large-scale prenatal microarray studies have
been published in which the diagnostic yields and the utility of
microarrays and conventional karyotyping have been compared.
In these studies, prenatalmicroarrayswere used for all categories
of prenatal diagnosis ascertainment including abnormal
ultrasound scans, maternal age, abnormal serum screening
result (with or without associated ultrasound), and parental
anxiety as well as a history of chromosome abnormalities.14–17
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In this paper, we have attempted to determine the
underlying rate of copy number changes with associated
clinical signiﬁcance (pCNCs) that can be detected by
microarrays in the prenatal diagnostic setting but have
restricted our inclusion criteria to those cases where a pCNC
has been detected in the presence of a normal conventional
karyotype. This review therefore excludes the evaluation of
cases where normal microarray results may mask a balanced
chromosome rearrangement that could have clinical signiﬁcance,
for example apparently balanced translocations or inversions in
conjunction with normal microarray proﬁles. We have presented
our results to try and estimate the overall detection rate of prenatal
pCNCs within the subclassiﬁcations of primary referral criteria.
METHODS: INCLUSION AND EXCLUSION CRITERIA
The search for suitable papers focused on prenatal studies
using microarray technology. The advanced search function
of the NCBI database, online resource PubMed (http://www.
ncbi.nlm.nih.gov/pubmed/advanced), was used with the word
‘prenatal’ combined with the following terms to describe
microarrays: ‘microarray’, ‘array’, ‘chomosomal microarray’,
‘array comparative genomic hybridisation’, ‘cma’, ‘CGH’ and
‘aCGH’. The titles and abstracts of the identiﬁed articles were
then checked against predetermined criteria for eligibility.
Bibliographies of relevant papers were manually interrogated
for further papers not identiﬁed by electronic searches. Experts
in the ﬁeld were also contacted for completeness of the
literature review (Lisa G. Shaffer and Jill A. Rosenfeld).
Our initial review of the literature identiﬁed 22 suitable
papers5–26 published between 2005 and 2013, which were then
subdivided into those where all categories of prenatal
ascertainment were included in the study design14–17 and those
where the analyses were restricted to fetuses presenting with
an abnormal ultrasound scan.5–12 It should be noted that only
papers where the microarray results, conventional karyotypes
and the ﬁnal clinical interpretations were all recorded have been
included in this review. The strict inclusion criteria of papers also
required the ability to identify the number of cases from each
ascertainment category with a pCNC in the presence of a normal
karyotype, calculate the total number of karyotypically normal
cases tested by CMA belonging to each category and correlate
speciﬁc raw copy number change data supplied by the authors
to numbers provided in their summary tables. If it was not
possible to elucidate this information from the paper, or obtain
it through personal communication with the authors, then the
paper was not included in the review. Based on these inclusion
criteria, the relatively large data sets from Breman et al.,19 Park
et al.18 and Armengol et al.20 were not included in the ﬁnal tables.
Therewere a number of difﬁculties encounteredwhen trying to
make direct comparisons between studies including the
following: (i) We have used and presented, without further
interpretation or comment, the genome coordinates and clinical
interpretation of pCNCs as published by the individual groups
and have reproduced the original calls and associated
interpretations in the Appendices. (ii) The studies included have
used a variety of microarray platforms comprising differences in
design and resolution (e.g. from ‘targeted’ 1Mb BAC arrays to
customdesigned 44k oligo or 125k SNP arrays). It should be noted
that we have only included abnormalities involving a change in
copy number and have therefore excluded abnormalities such
as uniparental disomy, which were detected by SNP arrays. (iii)
We made the decision not to include copy number changes that
were classiﬁed purely as VOUS. It should be noted here that some
authors (e.g. Wapner et al.14) include a number of potentially
signiﬁcant VOUS within their category of copy number changes
with clinical signiﬁcance, and we have included these cases
within the ‘pCNC’ group to try and determine the underlying rate
of cases deemed to have clinical consequences. VOUS rates
frequently depend on both the coverage of the array and the
laboratory reporting policy employed, making comparisons
across studies difﬁcult to do meaningfully. The stratiﬁcation of
the relative risk associated with any particular VOUS can also
determine whether it is considered to fall within a low, moderate
or high risk of adverse clinical consequences, and this stratiﬁcation
is reﬂected in the evidence-based subclassiﬁcation of VOUS as
outlined by the International Standards for Cytogenomic Arrays
(https://www.iscaconsortium.org/). In many of the papers
reviewed, no such risk stratiﬁcation was presented with the
exception of Wapner et al.14 who employed an expert review
panel to stratify risks associated with VOUS encountered
throughout the course of their study. Although the clinical
management of VOUS especially within the prenatal setting is
important, we felt that the focus of this review should be
restricted to those cases that were interpreted and therefore
reported to have clinically signiﬁcant prenatal pCNCs in the
presence of a normal karyotype.
RESULTS
A list of the published results can be found in the online
appendix. The inclusion criteria used in this review meant that
a number of relatively large-scale studies were not included
principally because it was not possible to correlate individual
karyotypic andmicroarray results18 and/or to break down results
by different ascertainment groups.19,20 Other studies were not
cited individually because their results were included in other
large-scale studies (e.g. Kleeman et al.,13 Maya et al.21 and
Coppinger et al.22 are included in the study by Shaffer et al.15).
Overall prenatal detection rate for pCNC in the presence of a
normal conventional karyotype
In Table 1, it can be seen that we have limited our review to four
large-scale studies in which the data are broken down into three
main ascertainment categories. It should also be noted that
because of differing study designs, there is signiﬁcant variability
with respect to the numbers reﬂected in the ascertainment
groups; for example, ~51%and~38%of cases recruited byWapner
et al.14 and Fiorentino et al.,17 respectively, were for advanced
maternal age compared with only 6% by Shaffer et al.15 By
comparison, the proportion of cases recruited because of an
abnormal ultrasound ranged from ~2.5% by Fiorentino et al.17 to
~80% by Shaffer et al.15 Despite this variation in study design we
decided to pool these data, which results in 25% of cases recruited
following an abnormal ultrasound scan, 41% with advanced
maternal age and 34% for the other ascertainment categories.
These pooled data show that in the presence of a normal
conventional karyotype, 295/12 362 (2.4%) of cases reported
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overall were found to have a pCNC compared with 201/3090
(6.5%) following an abnormal ultrasound, 50/5108 (1.0%) when
ascertained because of increased maternal age and 44/4164
(1.1%) for all other ascertainment groups.
Fetuses presenting with ultrasound abnormalities
The results for the eight targeted studies included in these
analyses5–12 are summarised in Table 2. Amongst these targeted
studies, the detection rate for pCNCs ranged from 6.1% to 13.3%,
but by pooling these data, 61/640 (9.5%) cases were interpreted
to have a pCNC. In Table 2, we have also included the abnormal
ultrasound abnormality ascertainment category from Wapner
et al.,14 Shaffer et al.,15 Lee et al.16 and Fiorentino et al.,17 from
which it can be seen that 262 of the 3730 (7.0%) abnormal
ultrasound cases overall were classiﬁed as having pCNCs.
DISCUSSION
The primary purpose of this review was to estimate the ‘added’
diagnostic value of microarray technology when applied
to cytogenetic prenatal diagnosis especially in those cases where
conventional G-banded analysis provides a normal chromosome
result. The headline ﬁgures are compelling in that from all
ascertainment groups comprising 12362 cases, microarrays
revealed 295 (2.4%) of cases with cryptic abnormalities interpreted
to have clinical signiﬁcance to the ongoing pregnancy, and this
increases to 7.0% of cases following an abnormal ultrasound scan,
and in ~1% of combined cases with advanced maternal age or
other referrals such as parental anxiety, history of chromosome
abnormality or an abnormal serum screening result. The
detection of these abnormalities is in addition to those seen by
conventional karyotyping, as all of the cases considered here were
karyotypically normal by routine chromosome analysis.
Current conventional prenatal diagnosis requires an invasive
procedure (amniocentesis or chorionic villus sampling) with an
associated risk of miscarriage of approximately 0.5% to 1%.27 In
many countries, the offer of an invasive procedure is usually
preceded by maternal serum and/or ultrasound screening
designed to stratify the risk primarily of Down syndrome in the
Table 1 Summary of pCNC microarray ﬁndings in routine prenatal diagnosis in the presence of a normal karyotype
Study
Sample
sizea Platform
Total
pCNC (%)
Ascertainment
Abnormal
ultrasound (%)
Maternal
age (%)
Other
(%)b
Wapner et al.14 3822 Targeted with 1Mb backbone 96 (2.5) 45/755 (6.0) 34/1966 (1.7) 17/1101 (1.5)
Shaffer et al.15 2587 Various 142 (5.5) 131/2081 (6.3) 0/161 (0.0) 11/345 (3.2)
Lee et al.16 3080 BAC targeted/60k oligo 35 (1.1) 20/180 (11.1) 10/1891 (0.5) 5/1009 (0.5)
Fiorentino et al.17 2873 BAC targeted 22 (0.8) 5/74 (6.8) 6/1090 (0.6) 11/1709 (0.6)
Total 12362 Various 295 (2.4) 201/3090 (6.5) 50/5108 (1.0) 44/4164 (1.1)
aNormal conventional karyotypes only.
bIncluding parental anxiety, history of chromosome abnormality, and abnormal serum screening result.
Table 2 Prenatal microarray studies focused on abnormal ultrasound (AUS) only
Sample sizea Platform No. pCNC pCNC %
AUS only studies
Tyreman et al.5 106 Affymetrix Gene Chip 6.0 11 10.4
D’Amours et al.6 49 BAC/105 and 135k oligo 6 12.2
Evangelidou et al.7 15 1Mb BAC 2 13.3
Valduga et al.8 50 44k oligo 5 10.0
Faas et al.9 30 250k SNP 2 6.7
Srebniak et al.10 199 105k SNP 16 8.0
Le Caignec et al.11 49 BAC targeted 3 6.1
Rooryck et al.12 142 60k oligo 16 11.3
Subtotal 640 61 9.5
Other studies
Wapner et al.14 755 Targeted with 1Mb backbone 45 6.0
Shaffer et al.15 2081 Various 131 6.3
Lee et al.16 180 BAC targeted/60k oligo 20 11.1
Fiorentino et al.17 74 BAC targeted 5 6.8
Subtotal 3090 201 6.5
Combined studies 3730 262 7.0
aNormal conventional karyotypes only.
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index pregnancy. However, the increasing use of high resolution
fetal ultrasound, particularly in the late second and early third
trimesters, may reveal detailed abnormal phenotypes that may
be associated with more subtle chromosome imbalances.
Conventional prenatal cytogenetics has long been seen as the gold
standard for chromosome diagnoses, but the resolution afforded
by conventional G-banded chromosomes means that the vast
majority of imbalances <6–10Mb will go undetected.
From the results presented here, it is clear that the majority of
studies to date have focused their ascertainment on cases with
abnormal fetal ultrasound scans. This approach provides the
highest rate of clinically relevant copy number changes in the
presence of a normal conventional karyotype. However,
although the overall pick-up rates in the non-ultrasound
ascertainment groups is ~1%, on a population level, this
represents a large number of cases where clinically relevant copy
number changes will go undetected if microarray technology is
applied only to fetuses with an abnormal ultrasound.
Furthermore, current prenatal diagnosis requires an invasive
procedure with an ~0.5% to 1% associated risk of miscarriage,27
and with the very low sensitivity of conventional cytogenetics
to detect clinically signiﬁcant chromosome abnormalities
smaller than 6 to 10Mb, it could be argued that once the invasive
procedure has been carried out then microarray should be the
frontline test once aneuploidies have been excluded by other
methodologies (e.g. QF-PCR). The adoption of prenatal
microarrays will also be signiﬁcantly inﬂuenced by the method
of healthcare delivery in any given country, especially whether
such provision is publically or privately funded.
In this review, we have taken at face value the authors’
categorisation of copy number changes especially those that
have been placed within the ‘clinically relevant’ category.
Antenatal diagnosis presents unique challenges especially when
a clinician is confronted with a variant of unknown signiﬁcance,
and these challenges are often compounded by trying to match
the antenatal phenotype with the genotype offered by the
microarray results. In one of the large-scale studies reviewed
here,14 genetic counselling was moderated by a review panel,
which considered a number of the VOUS individually and came
to a consensus as to whether it should, or should not, be
reported back to the parents. Although in many instances a
direct phenotype–genotype correlation can be made between
an increasingly large number of pCNC and speciﬁc fetal
phenotypes (e.g. a fetal outﬂow tract cardiac abnormality and
a 22q11.2 DiGeorge deletion), serious consideration needs to
be given to how copy number changes with known reduced
penetrance and possible neurological involvement (e.g.
15q11.2 BP1–BP2 deletions) should be interpreted when
detected antenatally. One potential source of assistance with
such interpretation may be provided by penetrance estimates
obtained by using Bayesian analysis models to compare the
copy number variation frequencies in both control and clinically
affected postnatal cohorts.28 A clear strategy will also be
required for the handling of ‘incidental ﬁndings’, for example
an X-linked deletion inherited from a phenotypically normal
carrier mother when ascertained in a female fetus.
It should also be stressed that access to regularly updated
international databases speciﬁcally designed to help facilitate
genotype–phenotype correlations for copy number changes,
neurodevelopmental phenotypes and congenital abnormalities
in the postnatal setting will provide essential interpretative tools
in the prenatal application of microarrays. Sites such as
DECIPHER (http://decipher.sanger.ac.uk/), the International
Standards for Cytogenomic Arrays (https://www.iscaconsortium.
org/) and also multiple links via the major genome web browsers
notably Ensembl (http://www.ensembl.org/Homo_sapiens/Info/
Index) and the University of California Santa Cruz (http://
genome.ucsc.edu/cgi-bin/hgGateway) all have updated relevant
information concerning genotype–phenotype correlations. In
the prenatal setting, it will also be crucial that expert
interpretation of VOUS is monitored by experts in both Clinical
Genetics and Molecular Cytogenetics before reports are issued
to patients and their clinicians.
Rapid technological advances, especially the use of massively
parallel sequencing to analyse cell-free DNA circulating in
maternal plasma, raise the possibility that prenatal microarrays
may have a limited time frame for clinical implementation. There
are already a number of proof-of-principle studies that have
demonstrated the feasibility of using non-invasive next generation
sequencing approaches to detect not only the common
aneuploidies but also unbalanced chromosome abnormalities
including micro-deletions and micro-duplications.29–32 The pace
at which these technologies will be applied to non-invasive
prenatal testing will increase exponentially over the coming
months providing signiﬁcant challenges to all healthcare
providers for assessing the most effective way of implementing
these novel approaches. In any event, it is clear that the current
model of screening followed by an invasive test and conventional
karyotyping will soon be replaced by molecular approaches.
CONCLUSION
Despite the perceived difﬁculties of implementing prenatal
microarrays diagnostically, especially those associated with the
discovery of VOUS and rarer incidental ﬁndings, the headline
ﬁgures presented here indicate that microarray technology could
and indeed should be the frontline prenatal test in the presence
of a fetal structural abnormality. Furthermore, we argue that with
a pick-up rate of at least 1% greater than that being achieved by
karyotyping in the other ascertainment groups, and with the ever
increasing availability of data to help with copy number change
interpretation, the data presented here also provide support to
the notion that microarrays should be the frontline test for all
prenatal diagnoses regardless of ascertainment category.
WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Microarray testing gives an increase in detection rate of unbalanced
structural abnormalities in both the postnatal and prenatal contexts.
WHAT DOES THIS STUDY ADD?
• This work attempts to calculate the overall detection rate, and the
detection rates for different ascertainment categories, of clinically
signiﬁcant prenatal copy number changes detected by microarrays
in the presence of a normal conventional karyotype by combining
data obtained from several published studies.
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